Previous close | 4.0250 |
Open | 0.0000 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.0000 - 0.0000 |
52-week range | |
Volume | |
Avg. volume | 8,806 |
Market cap | 520,882 |
Beta (5Y monthly) | 0.73 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.9300 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NANTES, France, December 11, 2023--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210313768/en/
NANTES, France, November 21, 2023--OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company has entered into a collaboration with GenDx (a Eurobio Scientific Company, a key player in the field of specialty in vitro diagnostics) to develop and validate a companion diagnostic (CDx) test to support the confirmatory pivotal Phase 3 clinical trial of Tedopi® cancer vaccine candidate in preparation in Non-Small Cell Lung Cancer (NSCLC) second line treatment. GenDx, o
NANTES, France, October 23, 2023--OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody